Candesartan Cilexetil and Hydrochlorothiazide Tablets
Reason Out-of-specification organic impurity results obtained during routine stability testing.
14,801 recalls, newest first
Reason Out-of-specification organic impurity results obtained during routine stability testing.
Reason Labeling: Not Elsewhere Classified. Container packaging is made, formed or filled to be misleading, resembling food and drink pouches
Reason Failed Impurities/Degradation - Out-of-specification results for Fluocinolone Acetonide impurity.
Reason Microbial Contamination of a Non-Sterile Product: Product tested positive for Cronobacter Sakazakii.
Reason Microbial Contamination of a Non-Sterile Product: Product tested positive for Cronobacter Sakazakii.
Reason Microbial Contamination of a Non-Sterile Product: Product tested positive for Cronobacter Sakazakii.
Reason Failed Impurties/Degradation Specifications: out of specification results for an impurity for one lot
Reason Presence of Foreign Tablets/Capsules: Metformin 1000mg with different imprint was found in bottles.
Reason Subpotent Drug: Product testing identified a decreased level of the active ingredient, Cysteamine HCl.
Reason CGMP Deviations: Detection of N-nitrosodimethylamine (NDMA) impurity in finished drug product.
Reason Labeling: Product Contains Undeclared API; Incorrect formulation
Reason Subpotent Drug: FDA analysis found these products to be less than the labeled claim for the levothyroxine (T4) portion of the product.
Reason Subpotent Drug: FDA analysis found these products to be less than the labeled claim for the levothyroxine (T4) portion of the product.
Reason CGMP deviations; repackaged product was recalled by the manufacturer because it was manufactured under the same conditions as products found to be sub-potent.
Reason Subpotent Drug
Reason Defective Delivery System: Sustained trend of failure to dispense complaints.
Reason cMGP Deviations: Drug products repackaged into pouches without supporting stability studies.
Reason cMGP Deviations: Drug products repackaged into pouches without supporting stability studies.
Reason cMGP Deviations: Drug products repackaged into pouches without supporting stability studies.
Reason Chemical Contamination and Subpotent Drug: FDA analysis found product to contain methanol and below label claim for ethanol.
Reason Failed Impurities/Degradation Specifications; high out of specification results obtained at the 9 month stability timepoint
Reason Labeling: Incorrect or Missing Package Insert: The package insert included in the finished product is for the Canadian market and is not part of the current approved drug labeling.
Reason Failed Stability Specifications: Below specification result for buprenorphine release rate.
Reason CGMP Deviations
Reason CGMP Deviations: Product manufactured in a facility where methanol was found in other distributed lots of product.